Clinical trial · Observational
PDL1 in Ovarian High Grade Serous Carcinoma
Prognostic Value of PDL1 in Ovarian High Grade Serous Carcinoma
NCT04507191CI-TRIAL-00046544completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the main purpose is to study the prognostic effect of PDL1 in ovarian cancer especially HGSC. Therefore, in the present study the investigators analyzed the expression of PDL1in HGSC by immunohistochemistry, and results were correlated to prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immunohistochemical staining | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- number of slides stained positive to PDL1 marker
- timeFrame
- 7 years from 2012 to 2019
- description
- using immunohistochemical staining for PDL1 markers for all slides of cases with ovarian tumor
Secondary outcomes (1)
- measure
- correlation between PDL1 expression to clinicopathological parameters of ovarian high grade serous carcinoma
- timeFrame
- 7 years from 2012 to 2019
- description
- correlation between PDL1 expression to criteria as ascites, peritoneal nodules and metastasis
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patients diagnosed with primary ovarian cancer Exclusion Criteria: * patients with metastatic ovarian cancer
References
Publications (0)
Data not yet available
No reference posted for this study.